El interés en corto de Redhill Biopharma da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Redhill Biopharma. Los datos de interés en corto se actualizan cada dos semanas.

Redhill Biopharma (NASDAQ:RDHL) Bolsa, Informe de interés en corto

Redhill Biopharma

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma Ltd

Groupon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grpn#NASDAQ">GRPN</a>) has seen its stock decline 25.2% year to date (YTD) against the Zacks Internet-Commerce industry&#39;s growth of 22.9%, the broader retail sector&#39;s return of 19.4% and the S&amp;P 500 index&#39;s rally of 20%.
GRPN, which has emerged as a two-sided global marketplace company, has been suffering from its weakening momentum in the international market. Unexpected site stability issues related to its cloud migration project have also been heavily affecting the company&#39;s performance.
Groupon&#39;s business model makes it heavily dependent on daily deals, which is a major headwind. Since most of the offerings are consumer discretionary products, demand is heavily dependent on macroeconomic conditions. Given this, the ongoing market uncertainties, persistent inflation, looming recessionary fears, changing consumer demand and spending patterns are dampening the company&#39;s near-term prospects.
<h2>Year-to-Date Price Performance</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/40/80256.jpg?v=610392595" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
GRPN&#39;s bearish guidance is a negative. For 2024, the company expects revenues between $495 million and $515 million, indicating a year-over-year change between (4%) and 0%. The Zacks Consensus Estimates for 2024 revenues is pegged at $514.51 million, implying a year-over-year decline of 0.1%.
The company operates in a highly competitive market, wherein it faces significant competition from the likes of Yelp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yelp#NYSE">YELP</a>), Rakuten, Travelzoo (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tzoo#NASDAQ">TZOO</a>) and Wowcher.
Groupon&#39;s solid momentum in its marketplace platform and strength in its e-commerce business model are major positives. Its large-scale global operations and growing relationship with third-party merchants reflect the company&#39;s upside potential, which bodes well for its long-term prospects.
Given the YTD dip in GRPN shares, investors are questioning whether this is the right time to buy the stock. Let us explore this in more detail.
<h2>E-commerce Strategies to Drive GRPN&#39;s Prospects</h2>
Groupon, through its e-commerce platform, offers numerous deals that can be accessed by users anywhere at any time.
GRPN&#39;s strategy to build a trusted marketplace, wherein customers purchase local services and experiences, is a major positive. For this, the company&#39;s growing efforts to build long-term relationships with local merchants to strengthen its inventory selection remain noteworthy.
It strives to deliver enhanced customer experience through inventory curation and improved convenience in order to boost purchase frequency on its platform.
To strengthen the platform, the company is lifting restrictions on its deeply discounted deals and is enabling customers to purchase such deals more than once to improve the frequency and drive growth in billings.
Growing momentum across the North America region has been driving growth in the company&#39;s Local segment, which contributes the most to GRPN&#39;s total revenues and remains crucial for its e-commerce business. In second-quarter 2024, Local revenues were $114.1 million (92% of total revenues), driven by North America Local revenues, which grew 7.3% year over year.
Groupon&#39;s long-term prospects rest upon its ability to offer more innovative products and build a broader Local e-commerce platform.&nbsp;
The company&#39;s strengthening supply drivers for North America Local are tailwinds. Groupon is witnessing growing traction among large enterprise merchants, thanks to expanding 
relationships with existing partners, and the addition of brands to the platform.
GRPN&#39;s initiatives to remove lower-quality deals from its site that do not align with the brand promise are a plus. Groupon also made substantial progress in curating its deals, with an enhanced presentation, improved deal copy and better images.
Solid demand for family-friendly activities, ranging from trampoline parks and bowling alleys to amusement parks and water parks, is another positive. The company expects to see continued growth in these areas in the days ahead.
Growing momentum in Groupon&#39;s latest initiative called Flash Sale, which was tested first in first-quarter 2024 with one enterprise merchant, is noteworthy. The Flash Sale concept boosted its performance and, hence, the company expanded this program in second-quarter 2024, running over a dozen flash sales with existing merchants to drive performance and boost engagement on its site. Although the initiative is fresh and new, it reflects the company&#39;s potential to expand its business by developing products to cross-sell and up-sell into its supply base.
Groupon&#39;s AI initiative is a major plus. AI integration has enabled it to improve the copywriting of its deals and deal creation process. It leverages AI on projects in product and engineering to improve deal recommendation and quality assurance. Improvements in enterprise sales organization and process changes, combined with value proposition changes, continue to contribute to growth in its enterprise accounts.
<h2>Upward Earnings Trend Paints Bright Picture for GRPN</h2>
Investors are turning bullish about Groupon&#39;s upside potential, which is reflected in the upward revisions in earnings estimates.
For 2024, the Zacks Consensus Estimate for earnings is pegged at 47 cents per share, whereas the company reported a 2023 loss of 52 cents. The estimate has been revised upward by 56.7% over the past 60 days.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fa/80258.jpg?v=1264508241" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h2>Attractive Valuation: A Silver Lining for GRPN</h2>
Groupon is currently trading at a discount with a forward 12-month Price/Sales of 0.7X compared with the industry&#39;s 1.72X and lower than the median of 0.84X. This indicates an excellent opportunity for investors.
GRPN also has a Value Score of B, which is hard to ignore.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/56/80257.jpg?v=1027816364" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h2>Conclusion</h2>
Despite near-term hurdles, Groupon&#39;s strong marketplace, robust e-commerce business model, growing merchants base and solid supply drivers present a solid investment opportunity for growth-seeking investors.
Its attractive valuation and Growth Score of A make a compelling case for buying the GRPN stock at its current levels.
Groupon sports a Zacks Rank #1 (Strong Buy) at present.
<a href="https://www.zacks.com/stock/news/2345645/groupon-shares-decline-25-2-ytd-should-you-buy-the-dip-right-now?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2345645">To read this article on Zacks.com click here.</a>

Earnings

Mid Cap

News

Guidance

Retail Sales

Small Cap

Markets

Analyst Ratings

Tech

Trading Ideas

GRPN

TZOO

YELP

Groupon Shares Decline 25.2% YTD: Should You Buy the Dip Right Now?

Texas Attorney General Ken Paxton has filed a lawsuit against several major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a conspiracy to <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40560002/governments-suing-pharmacy-benefit-managers-over-insulin-prices-have-long-benefited-from-their-r" rel="noreferrer noopener">inflate insulin prices</a>.
The <a target="_blank" href="https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers" rel="noreferrer noopener">lawsuit</a> targets pharmaceutical companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and PBMs, including Cigna Corp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts and CVS Health Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) CVS Pharmacy, accusing them of engaging in an unlawful scheme to raise insulin prices.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices</a>.
According to the lawsuit, insulin manufacturers artificially raised the prices of their drugs while paying PBMs a significant, undisclosed portion in return for preferred placement in PBM offerings.
The PBMs allegedly rewarded the manufacturers with the highest list prices by giving their products preferred status while excluding more affordable alternatives.
These insulin drugs, which cost manufacturers less than $2 to produce, were introduced in the late 1990s at $20 per vial. However, prices have now soared to between $300 and $700 per vial.
Over the past decade, some manufacturers have raised insulin prices by as much as 1,000%.
Paxton expressed outrage over the alleged scheme, stating, "This is a disturbing conspiracy by which pharmaceutical companies were intentionally and artificially inflating the price of insulin. Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could." He vowed to hold these companies accountable for their actions.
The complaint further claims that while PBMs have publicly positioned themselves as entities working to reduce drug prices and improve treatment access, their actions tell a different story.
The lawsuit argues that the PBMs have colluded with insulin manufacturers to manipulate the market for their financial gain, all at the expense of Texas diabetics and healthcare payors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41171469/uber-avride-join-forces-for-autonomous-delivery-partners-with-enso-for-low-emission-ev-tires" target="_blank" rel="noreferrer noopener">Uber &amp; Avride Join Forces for Autonomous Delivery; Partners With ENSO For Low-Emission EV Tires</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Government

Large Cap

Health Care

Legal

General

Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%

Deutsche Bank analyst Scott Deuschle maintains Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Buy, raising the <a target="_blank" href="https://www.benzinga.com/quote/LMT/analyst-ratings" rel="noreferrer noopener">price forecast from&nbsp;$600&nbsp;to&nbsp;$620.</a>
The analyst suggests that Lockheed Martin likely prefunds its pension in the fourth quarter, although the company may delay a formal announcement until after it&#8217;s completed.
Deuschle adds that the associated debt issuance for this funding is expected to occur sooner.
The analyst forecasts third-quarter EPS of $6.70, approximately 4% above the Street&#8217;s estimate of $6.47.
Deuschle sees revenue of around $17.4 billion, which is $100 million below the Street&#8217;s expectation, as the analyst incorporates the $500 million F-35 contract delay impact at Aeronautics, which is not fully reflected in the Street&#8217;s projections.
The analyst identifies the greatest upside potential in Space, noting that underlying margins excluding United Launch Alliance (ULA)&nbsp;are expected to decline significantly in the second half.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/41012117/lockheed-martins-unit-secures-contract-for-ch-53k-gearbox-assemblies" rel="noreferrer noopener">Lockheed Martin&#8217;s Unit Secures Contract for CH-53K Gearbox Assemblies</a>
This outlook seems conservative, considering that two major contracts—Orion and OPIR—are entering a highly mature phase of their production lifecycle.
The analyst projects a third-quarter revenue beat, which may lead to an upward revision of the full-year revenue guidance, potentially nearing $72 billion.
Deuschle also sees a 1%-2% increase to the midpoint of the full-year segment EBIT guidance, especially if EBIT upside is realized in Space during the third quarter, as seen in the first half.
The analyst sees the company offer some indication for 2025 financial trends.
Given the firm&#8217;s conservative track record, the analyst sees the company is likely to project approximately 3% revenue growth and reiterates its target for 10-20 basis points of margin expansion.
Deuschle also projects a dividend increase announcement ahead of earnings, and the buyback authorization will likely be topped up.
Price Action: LMT shares are trading lower by 0.29% to $601.79 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41166723/how-many-evs-has-tesla-delivered-produced-each-quarter-a-look-at-the-results-since-2019" target="_blank" rel="noreferrer noopener">How Many EVs Has Tesla Delivered, Produced Each Quarter? A Look At The Results Since 2019</a></li>
</ul>

Analyst Color

Equities

Price Target

Reiteration

Lockheed Martin's Greatest Upside Potential Is In Space: Analyst Sees Dividend Hikes, Buyback Top Ups

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is gearing up for a $783 million debt sale, coinciding with a busy October that features the highly <a href="https://www.benzinga.com/news/24/09/40808924/tesla-robotaxi-event-to-be-held-in-los-angeles-on-1010-says-senior-company-exec-existing-shareholder">anticipated Robotaxi Day.</a>
What Happened: Tesla, which recently<a href="https://www.benzinga.com/news/24/10/41141444/tesla-stock-plunges-3-despite-q3-deliveries-exceeding-consensus-and-growing-year-over-year"> reported third-quarter delivery</a> and production figures, could price its debt sale as early as next week.
The debt sale, which is being run by Societe Generale, would see Tesla provide the backing of prime borrowers' car leases, as reported by <a href="https://www.bloomberg.com/news/articles/2024-10-03/tesla-plans-783-million-debt-sale-backed-by-prime-leases?srnd=homepage-americas&amp;sref=TBDibEcD">Bloomberg</a>.
According to the report, this would mark Tesla&#8217;s second financing this year. Tesla raised $750 million in March.
By leveraging its car leases, Tesla would join other automakers in using asset-backed securities as a tool to finance future growth.
Tesla has previously used asset-backed securities for funding, but not as much as its U.S. automotive rivals, the report said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100324">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
 What's Next: The financing news follows Tesla&#8217;s third-quarter delivery figures and comes ahead of several key October catalysts, which could lead to significant volatility in the company&#8217;s stock.
Tesla will host its Robotaxi Day on Oct. 10 and report third-quarter financial results on Oct. 23, which mark two of the biggest company events in the last three months of the calendar year.
The company will<a href="https://www.benzinga.com/news/24/09/41027049/tesla-returns-to-paris-motor-show-for-first-time-in-6-years-cybertruck-to-be-featured-will-elon-musk"> also exhibit multiple models</a>, including the Cybertruck, at the Paris Auto Show from Oct. 14 to Oct. 20. This marks Tesla's first appearance at the auto show in six years.
TSLA Price Action: Tesla stock was down 4% to $238.26 on Thursday, compared to a 52-week trading range of $138.80 to $271.00. It is down 4.1% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41166723/how-many-evs-has-tesla-delivered-produced-each-quarter-a-look-at-the-results-since-2019">How Many EVs Has Tesla Delivered, Produced Each Quarter? A Look At The Results Since 2019</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

TSLA

Tesla Uses Auto Leases To Back $783M Debt Sale: Report

WIIM

FFWM

First Foundation shares are trading higher after the company announced it will be reclassifying $1.9 billion from its multifamily portfolio from loans held to maturity to loans held for sale.

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) owned streaming platform AppleTV+ is one of the smaller players in<a href="https://www.benzinga.com/topic/streaming"> the streaming market.</a>
When it comes to star power, Apple has landed some big names. A movie with two of the biggest actors around could help boost the future outlook.
What Happened: With ballooning budgets and tough decisions on whether to play movies in cinemas, and then stream them on AppleTV+, the technology giant recently announced it would <a href="https://www.benzinga.com/news/24/09/41073117/apples-reviews-strategy-cuts-film-budgets-after-blockbuster-spend-whats-next-for-apple-tv">scale back movie budgets.</a>
That decision comes after Apple recently debuted "Wolfs" in a limited theatrical release ahead of its Sept. 27 streaming premiere on AppleTV+.
While most films starring George Clooney and Brad Pitt, would command a premium budget and likely see a strong box office run, the "Wolfs" stars have denied getting a reported $35 million each and said they were paid less for the film
After originally planning on releasing the movie widely in movie theaters, Apple made the decision to switch to a limited run ahead of the streaming premiere.
The decision may have paid off with Apple saying "Wolfs" is now the most viewed movie in AppleTV+ history, without providing a specific figure.
"Wolfs" helped boost viewership on AppleTV+ by 30% week-over-week after the movie's premiere according to a report from <a href="https://deadline.com/2024/10/george-clooney-brad-pitt-wolfs-most-viewed-movie-in-apple-tv-history-1236105000/">Deadline</a>.
The film, which premiered at the Venice Film Festival, has already been green lit for a sequel by Apple, with the film's writer and director Jon Watts returning.
"When George, Brad and Jon approached us with the idea for ‘Wolfs,' it was an easy call – a crackling, fun movie starring two Oscar winners who everyone knows are iconic together," Apple Original Films' head of features Matt Dentler said.
Dentler said AppleTV+ could be the "home for the world's most talented artists to create and deliver their best work" and the audience viewership has been existing.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100324">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It Matters: Apple TV+ was launched on Nov. 1, 2019. It marked Apple&#8217;s entry into the competitive streaming market, which is <a href="https://www.benzinga.com/news/24/04/38337256/netflix-once-again-evolved-and-eclipsed-its-streaming-war-rivals">dominated by </a>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
While the decision not to run the movie in theaters may have been tough for Apple and left money on the table, it likely means a boost to streaming viewership figures and potentially an uptick in subscriber.
Apple has <a href="https://www.benzinga.com/24/03/37558754/apples-1b-gamble-on-3-blockbusters-analyzing-box-office-results-streaming-impact-and-oscar-nominatio">seen recent success </a>at the Academy Awards with "CODA," which won a historic Oscar for Best Picture at the 94th Academy Awards. 
Other Apple-produced movies also saw theatrical releases. They include:
<ul>
<li>&#8220;<a href="https://www.boxofficemojo.com/title/tt5537002/?ref_=bo_se_r_1" target="_blank" rel="noreferrer noopener">Killers of the Flowers Moon</a>&#8220;: $67.9 million domestic, $89 million international, $156.9 million global</li>
<li>&#8220;<a href="https://www.boxofficemojo.com/title/tt13287846/?ref_=bo_se_r_1" target="_blank" rel="noreferrer noopener">Napoleon</a>&#8220;: $61.5 million domestic, $159.5 million international, $221 million global</li>
<li>&#8220;<a href="https://www.boxofficemojo.com/title/tt15009428/?ref_=bo_se_r_1" target="_blank" rel="noreferrer noopener">Argylle</a>&#8220;: $44.2 million domestic, $48.2 million international, $92.5 million global</li>
</ul>
In total, the three movies cost around $700 million for Apple and grossed $470.4 million worldwide, according to BoxOfficeMojo.
While the box office figures didn't break even on costs, a studio source told Variety that both "Killers of the Flower Moon" and "Napoleon" were profitable thanks to other revenue streams.
Netflix, in contrast, rarely uses the theater distribution model for its films. But Apple has adopted a strategy of premiering its major films in theaters before offering them exclusively on its streaming platform, Apple TV+.
This model helps Apple recover some of its costs and could also help the company be a staple for award shows that require a theatrical run.
Apple finds itself in a difficult place with the need to spend more on content to boost subscribers, but also having less to spend on movies and content due to a smaller subscriber base. With the parent company a cash cow, Apple may be able to maintain losses for its streaming business if it chooses to, but could also push for a larger focus on profits.
Reports say Apple is considering<a href="https://www.benzinga.com/general/entertainment/24/07/40014040/apple-to-follow-netflix-disney-ad-supported-appletv-streaming-plan-could-launch-soon"> launching an ad-supported </a>streaming plan soon, which could help alleviate some of the revenue concerns and bring in more money to be spent on content.
The company&nbsp;<a href="https://www.benzinga.com/news/23/06/32764885/lionel-messi-joins-mls-in-surprise-move-heres-how-apple-could-have-played-into-decision-to-join-davi" target="_blank" rel="noreferrer noopener">previously acquired the rights</a>&nbsp;to Major League Soccer and select Major League Baseball games. The MLS bet paid off with superstar&nbsp;Lionel Messi&nbsp;joining the league and Apple&nbsp;<a href="https://www.benzinga.com/news/23/08/33737512/lionel-messis-inter-miami-stint-leads-to-explosive-surge-in-mls-streaming-subscribers-double" target="_blank" rel="noreferrer noopener">seeing a boost</a>&nbsp;in subscribers to the platform.
Apple will release "Blitz" in select theaters on Nov. 1 with a streaming premiere on AppleTV+ on Nov. 22. The company also has "F1," which stars Pitt, opening in theaters on June 25, 2025.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100324">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image: Shutterstock

Entertainment

AAPL

NFLX

Apple TV+ Scores Biggest Streaming Movie In History Thanks To George Clooney, Brad Pitt

Nike (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) shares fell after the Q1 report, which opened an opportunity for investors. The fall is due to numerous factors, including weaker-than-expected results, revoked guidance, and a CEO transition that is ultimately expected to turn the company around. The takeaway is that Nike faces headwinds and has a long road to recovery, but market support remains firm, and recovery is expected. The question is if now is the right time to buy or if the stock will make a deeper correction before the rebound begins.
The analysts are trimming targets but have yet to make any downgrades. The 19 MarketBeat tracks have the stock pegged at a Moderate Buy and trading near a floor in the low $70s. With this dynamic in play, the market will likely bottom soon and begin to rebuild the base. The critical drivers for the action going forward will be a recovery in wholesales and product innovation, the primary reasons for the company&#39;s weakness today. Nike&#39;s leaning into direct-to-consumer sales eroded wholesaler support, exacerbating market share losses related to innovation.&nbsp;
Nike did not make any significant product innovations for years until 2024, losing market share to start-ups like On Holdings (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/onon#NYSE">ONON</a>) and legacy shoemakers like Adidas (OTC: <a class="ticker" href="https://www.benzinga.com/stock/adddf#OTC">ADDDF</a>) and Deckers Outdoors (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/deck#NYSE">DECK</a>). On Holdings is growing at an industry-leading double-digit pace while Nike flounders in contraction. Even so, the new Nike pipeline depends on updates to existing Air technology, athlete partnerships to drive product changes, and streamlined production, which may not yield results quickly. The best estimates are for the changes to take effect in early 2026, more than eighteen months away.&nbsp;
<h2>Nike Had a Tough Quarter, But Not a Bad One</h2>
Nike had a tough time in Q1, but the business remains profitable, producing positive cash flow sufficient to sustain balance sheet quality and capital returns. The company reported $11.6 billion in net revenue, down 10.4% compared to last year, falling short of the consensus estimates but beating the bottom line. Revenue was impacted by weakness in Nike and Converse brands, DTC, and wholesales, with a contraction in the core footwear and apparel categories. Equipment is the single area of strength, up 34%, aiding bottom-line results.&nbsp;
The margin news is also mixed, with gross margin and selling, general, and administrative expenses (SG&amp;A) improving but offset by increased sales and tax expenses. The takeaway is that net income is down 28% year over year, and the diluted GAAP EPS is 26% but well above forecasts, reflecting operational improvements and quality. The net result is $0.70 in GAAP EPS, which is more than 3500 basis points above consensus, with margin quality expected to continue in the coming quarters.&nbsp;
The details that spooked the market are the retracted full-year guidance and delayed investor day conference, which brings an element of uncertainty to the outlook with the CEO change due soon. As it is, the company expects Q2 revenue to be down 8% to 10%, putting the H1 outlook in alignment with the prior forecast.&nbsp;
<h2>No Red Flags on Nike&#39;s Strong Balance Sheet: Capital Returns Can Run</h2>
As troubled as Nike is, the company produced a positive cash flow quarter and improved its balance sheet while sustaining dividends and share repurchases. The share repurchases topped $1 billion for the quarter, helping to reduce the average count by 2.7%, and will likely continue as the fiscal year progresses.&nbsp;
The dividend is also safe at roughly 50% of the quarterly earnings. However, the pace of annual increase will likely slow from double-digits into the low single-digits until growth is reinvigorated. Regarding the balance sheet, cash and assets are up compared to last year, and debt and equity are relatively flat, leaving the company in a net-cash position relative to its debt, with leverage low at 0.6x equity. Nike has work to do but is in a solid financial position, capable of making the necessary moves to achieve its goal.&nbsp;
<img alt="Nike NKE stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241002091343_chart-nke-1022024.png" style="height:423px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/originals/nikes-post-earnings-drop-presents-a-buying-opportunity/">Nike&#39;s Post-Earnings Drop Presents a Buying Opportunity</a>&quot; first appeared on MarketBeat.

Dividends

ADDDF

DECK

ONON

Nike's Post-Earnings Drop Presents a Buying Opportunity

Investors with a lot of money to spend have taken a bullish stance on Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CELH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Celsius Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 38%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $376,568, and 6 are calls, for a total amount of $212,218.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $17.5 to $130.0 for Celsius Holdings during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Celsius Holdings options trades today is 868.0 with a total volume of 2,525.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Celsius Holdings's big money trades within a strike price range of $17.5 to $130.0 over the last 30 days.
<h3>Celsius Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727983154_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$100.0</td>
<td>$98.35</td>
<td>$100.0</td>
<td>$130.00</td>
<td>$90.0K</td>
<td>218</td>
<td style="text-align: right;">9</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.3</td>
<td>$8.2</td>
<td>$8.3</td>
<td>$30.00</td>
<td>$73.0K</td>
<td>761</td>
<td style="text-align: right;">207</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.75</td>
<td>$6.65</td>
<td>$6.75</td>
<td>$40.00</td>
<td>$59.4K</td>
<td>2.4K</td>
<td style="text-align: right;">219</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.42</td>
<td>$35.50</td>
<td>$54.0K</td>
<td>37</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$5.45</td>
<td>$5.2</td>
<td>$5.31</td>
<td>$35.50</td>
<td>$53.1K</td>
<td>37</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About Celsius Holdings</h3>
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages (including those that are naturally caffeinated with stevia), Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
In light of the recent options history for Celsius Holdings, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Celsius Holdings</h3>
<ul>
<li>With a volume of 4,035,346, the price of CELH is down -0.66% at $30.25. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 33 days.</li>
</ul>
<h3>What Analysts Are Saying About Celsius Holdings</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $42.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Celsius Holdings, maintaining a target price of $47. 
&#x2A; An analyst from Roth MKM persists with their Buy rating on Celsius Holdings, maintaining a target price of $45. 
&#x2A; Maintaining their stance, an analyst from Roth MKM continues to hold a Buy rating for Celsius Holdings, targeting a price of $43. 
&#x2A; An analyst from B of A Securities has decided to maintain their Underperform rating on Celsius Holdings, which currently sits at a price target of $26. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Celsius Holdings with a target price of $51. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celsius Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

CELH

Looking At Celsius Holdings's Recent Unusual Options Activity

Financial giants have made a conspicuous bullish move on Hims &amp; Hers Health. Our analysis of options history for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) revealed 39 unusual trades.
Delving into the details, we found 58% of traders were bullish, while 28% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $756,530, and 28 were calls, valued at $3,089,081.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $30.0 for Hims &amp; Hers Health over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Hims &amp; Hers Health options trades today is 2581.74 with a total volume of 69,554.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Hims &amp; Hers Health's big money trades within a strike price range of $10.0 to $30.0 over the last 30 days.
<h3>Hims &amp; Hers Health Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727983149_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.25</td>
<td>$2.1</td>
<td>$2.2</td>
<td>$20.00</td>
<td>$1.0M</td>
<td>6.1K</td>
<td>5.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.8</td>
<td>$6.7</td>
<td>$6.8</td>
<td>$15.00</td>
<td>$152.3K</td>
<td>2.8K</td>
<td>947</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.05</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$13.00</td>
<td>$150.0K</td>
<td>1.4K</td>
<td>2.7K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.5</td>
<td>$6.4</td>
<td>$6.5</td>
<td>$15.00</td>
<td>$139.7K</td>
<td>2.8K</td>
<td>262</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$20.00</td>
<td>$125.0K</td>
<td>2.3K</td>
<td>640</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Having examined the options trading patterns of Hims &amp; Hers Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Hims &amp; Hers Health's Current Market Status</h3>
<ul>
<li>With a trading volume of 22,353,251, the price of HIMS is down by -10.18%, reaching $17.02.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 32 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Hims &amp; Hers Health</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $20.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Hims &amp; Hers Health, which currently sits at a price target of $20. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Hims &amp; Hers Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Check Out What Whales Are Doing With HIMS

Investors with a lot of money to spend have taken a bullish stance on ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ZIM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for ZIM Integrated Shipping.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 33%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $95,507, and 6 are calls, for a total amount of $311,252.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $25.0 for ZIM Integrated Shipping during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ZIM Integrated Shipping's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ZIM Integrated Shipping's substantial trades, within a strike price spectrum from $5.0 to $25.0 over the preceding 30 days.
<h3>ZIM Integrated Shipping 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727983144_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$17.0</td>
<td>$16.95</td>
<td>$17.0</td>
<td>$5.00</td>
<td>$93.5K</td>
<td>78</td>
<td>55</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.79</td>
<td>$0.66</td>
<td>$0.66</td>
<td>$25.00</td>
<td>$66.0K</td>
<td>15.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.95</td>
<td>$1.76</td>
<td>$1.95</td>
<td>$24.00</td>
<td>$58.5K</td>
<td>792</td>
<td>316</td>
</tr>
<tr>
<td>ZIM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$0.97</td>
<td>$0.0</td>
<td>$0.91</td>
<td>$22.00</td>
<td>$39.0K</td>
<td>97</td>
<td>432</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$1.92</td>
<td>$1.46</td>
<td>$1.69</td>
<td>$22.50</td>
<td>$33.8K</td>
<td>5.6K</td>
<td>200</td>
</tr>
</tbody>
</table>

<h3>About ZIM Integrated Shipping</h3>
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
After a thorough review of the options trading surrounding ZIM Integrated Shipping, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of ZIM Integrated Shipping</h3>
<ul>
<li>With a trading volume of 4,796,348, the price of ZIM is up by 1.24%, reaching $23.7.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 41 days from now.</li>
</ul>
<h3>Expert Opinions on ZIM Integrated Shipping</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $17.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Jefferies lowers its rating to Hold with a new price target of $25. 
&#x2A; In a cautious move, an analyst from JP Morgan downgraded its rating to Underweight, setting a price target of $10. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ZIM Integrated Shipping, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding ZIM Integrated Shipping's Options Activity: What's the Big Picture?

Oil is trading more than 5% higher Thursday on the heels of President Joe Biden&#8216;s statement that the U.S. spoke with Israel about a possible attack on Iran's oil facilities.
"We're in discussions about that,&#8221; Biden said during an interaction with reporters. 
Biden seemingly indicated he wasn&#8217;t partial to the idea of striking at Iran&#8217;s oil facilities, before cutting himself off: &#8220;I think that would be a little&#8230; anyway.&#8221; See video below.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Biden: Discussing Israeli strikes on Iran oil facilities &#x7C; AJ #shorts" width="500" height="281" src="https://www.youtube.com/embed/InF5MnsXAt0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
When one reporter asked whether Biden would &#8220;allow&#8221; Israel to retaliate against Iran, Biden swiftly corrected him: &#8220;First of all, we don&#8217;t &#8216;allow&#8217; Israel. We advise Israel.&#8221;
<a href="https://www.benzinga.com/news/23/10/35136071/israel-under-siege-unprecedented-hamas-attack-sparks-intense-clashes-netanyahu-says-we-are-at-war">Since Oct. 7, 2023</a>, Israel has been fighting Hamas in Gaza as well as Hezbollah in Lebanon. Both groups are considered terrorist organizations by the U.S. 
See Also: <a href="https://www.benzinga.com/news/24/10/41134015/jd-vance-tim-walz-debate-sets-a-different-tone-candidates-discuss-israel-iran-escalation-immigration">JD Vance, Tim Walz Debate Sets A Different Tone, Candidates Discuss Israel-Iran Escalation</a>
<h3 class="wp-block-heading">Oil And The Israel-Iran Conflict</h3>
Iran is the seventh-largest oil producer in the world. The country, which backs the Hezbollah militant group, exports around half its production abroad. 
China, where <a href="https://www.benzinga.com/markets/asia/24/08/40596334/asia-markets-mixed-europe-gains-crude-oil-falls-on-chinese-demand-concerns-global-markets-today-whil">oil demand is weak</a>, is its main customer.
Since Iran's <a href="https://www.benzinga.com/news/global/24/10/41126038/iran-attacks-israel-with-missiles-middle-east-tensions-escalates-s-p-500-stocks-bitcoin-fall-as-oil">missile attack on Israel</a> on Monday, the price of barrels has fluctuated. As of Oct. 3, the price of West Texas Intermediate (WTI) crude oil is $73.83 per barrel. This reflects a 5.32% increase from the previous day&#8217;s close of $70.10.
The price of Brent crude is approximately $77.76 per barrel. It has fluctuated within a range of $74.33 to $77.58 for the day.
The U.S., which is producing more oil under Biden than any other U.S. presidential administration, has been filling its reserves. The Biden administration acquired an additional <a href="https://www.benzinga.com/markets/eurozone/24/10/41146905/geopolitical-risks-may-be-biggest-threat-to-markets-boe-says">6 million barrels of crude</a> just this week.
It&#8217;s worth noting that ongoing violence in the Middle East puts the Straits of Hormuz at risk. A third of tanker traffic and a fifth of LNG frozen gas is transported through that passageway. 
The U.S. and its allies are likely determined to keep the Strait open due to its strategic importance. Any attempt to block the Strait could provoke military intervention.
Iran controls much of the northern coastline of the Strait and has previously threatened to block the passage in response to sanctions or conflicts with Western countries. 
<h3 class="wp-block-heading">Market Reaction</h3>
So far, market reaction to the Middle East conflict is relatively mute compared to February 2022 when Russia invaded Ukraine.
At the time, the oil market reacted with significant volatility and disruption, leading to a sharp rise in global prices. 
Brent crude, the global benchmark, surged above $100 per barrel for the first time since 2014, and by March 2022, it had briefly spiked to $139 per barrel, near the all-time high.
Oil-related exchange-traded funds, or ETFs, were trending up at last check Thursday afternoon. Here&#8217;s where they stand: 
<ul>
<li>United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) is up 4.05% to $75.71</li>
<li>Invesco DB Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBO#NYSE">DBO</a>) is up 4.08% at $15.06</li>
<li>SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) is up 3.1% at $139.56</li>
<li>Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) up 1.65% at $92.22</li>
<li>ProShares Ultra Bloomberg Crude Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCO#NYSE">UCO</a>) is up 6.59% at $28.81</li>
<li>VanEck Vectors Oil Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIH#NYSE">OIH</a>) is up 1.89% at $297.58</li>
</ul>
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/10/41170128/jobs-report-preview-could-september-labor-data-shift-feds-interest-rate-path">Jobs Report Preview: Could September Labor Data Shift Fed&#8217;s Interest Rate Path?</a></li>
</ul>
Image: Shutterstock

Regulations

Sector ETFs

Commodities

Politics

Global

ETFs

Oil Prices Rally: Biden Confirms US 'Discussions' With Israel About Striking Iran Facilities

Deutsche Bank analyst Scott Deuschle changed price targets and presented earnings previews for major Aerospace companies such as GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) and Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>).
The analyst writes that these stocks are well-insulated against end-market challenges and are likely to achieve the largest earnings beats and drive significant upward revisions.
GE Aerospace: The analyst raised the price target to $235 from $212 <a target="_blank" href="https://www.benzinga.com/quote/ge/analyst-ratings" rel="noreferrer noopener">while maintaining a Buy rating</a>.
Deuschle expects a 9% EPS beat in their base case and a 15% beat in the blue sky scenario for the third quarter.
In both cases, the analyst anticipates an increase in 2024 guidance, with a potential 7% EBIT rise if the blue sky scenario occurs.
Strong CSA collections from the summer flying season could drive free cash flow (FCF) above expectations, leading to an increase in FCF guidance, adds the analyst.
Overall, Deuschle says that they are optimistic ahead of the earnings release due to the potential for a significant beat and raise this quarter.
Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40986267/ge-aerospace-takes-flight-with-ai-wingmate-boosts-innovation-employee-productivity-with-microsof" rel="noreferrer noopener">GE Aerospace Takes Flight With AI Wingmate: Boosts Innovation, Employee Productivity With Microsoft&#8217;s Azure AI</a>
Howmet: The analyst raised the price target to $125 from $106 while <a target="_blank" href="https://www.benzinga.com/quote/hwm/analyst-ratings" rel="noreferrer noopener">maintaining a Buy rating</a>.
The analyst writes that the base case estimates third-quarter EPS at $0.68, above the Street&#8217;s $0.66, with a roughly 2% midpoint guidance increase.
The analyst cited upside drivers such as pricing strategies, strong execution allowing shipments above long-term agreement caps, and earlier-than-expected generation 2 LEAP HPT blade shipments.
Deuschle expects HWM to guide 2025 revenue in line with the Street (+10%), which could trigger further positive revisions, given a higher 2024 base and likely surprises in Engine Products EBITDA margins.
Read Next: <a target="_blank" href="https://www.benzinga.com//node/41171469" rel="noreferrer noopener">Uber &amp; Avride Join Forces for Autonomous Delivery; Partners With ENSO For Low-Emission EV Tires</a>
For Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), the analyst lowered the price target to $195 from $225 while <a target="_blank" href="https://www.benzinga.com/quote/BA/analyst-ratings" rel="noreferrer noopener">maintaining a Buy rating</a>.
The analyst anticipates a third-quarter free cash flow burn of ($4.0 billion), up from a previous estimate of ($2.4 billion), due to the strike&#8217;s impact on September deliveries and ongoing cash pressures in Boeing&#8217;s Defense segment.
The forecast includes a $1 billion EBIT loss at Boeing Defense Systems (BDS) and a $1.6 billion loss at Boeing Commercial Airplanes (BCA), adds the analyst.
Deuschle says that BCA loss forecast assumes a $1 billion forward loss on the 777X, reflecting delays in entry into service and increased costs related to union negotiations and wage hikes.
Also Read: <a href="https://www.benzinga.com/news/24/10/41170226/boeing-workers-union-says-decision-to-cut-health-care-for-33-000-is-unnecessary-and-cruel" target="_blank" rel="noreferrer noopener">Boeing Workers&#8217; Union Says Decision To Cut Health Care For 33,000 Is &#8216;Unnecessary And Cruel&#8217;</a>
Image via Shutterstock

GE and Howmet Poised for Strong Earnings as Aerospace Sector Stays Resilient: Analyst

The Western Union Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wu#NYSE">WU</a>) inked a deal with the Open Finance company, Khipu, enabling customers to transfer money digitally using any bank account in Chile.
The agreement incorporates Khipu&#39;s technology into Western Union&#39;s mobile app and website. Earlier, customers paying through a bank account had to leave the Western Union app or website and log into their bank&#39;s platform to complete the payment. This step is now removed as a result of the latest integration, allowing the entire transaction to be completed within the Western Union platform. The service is now available via the Western Union Chile app and website.
Western Union has also introduced a special promotion offer with a $0 fee for the first remittance made using the &quot;Online Bank Transfer&quot; option, thereby encouraging customers to explore the new service. The collaboration between WU and Khipu makes sure that cross-border payments can be made faster and more seamlessly by Chile&#39;s customers.
<h2>Benefits of the Recent Move to Western Union</h2>
The recent initiative reflects Western Union&#39;s sincere efforts to establish a solid footprint across the Chilean remittance market.&nbsp;
Moves similar to the latest one are indicative of Western Union&#39;s efforts to align with its global digital expansion strategy, designed to attract more customers through its diverse service offerings. Speedier money transfers brought about by integrating Khipu&#39;s technology into the WU platform are likely to result in the increased usage of its money transfer services. This move is likely to further boost the company&#39;s digital money transfer revenues in the days ahead.
Strategic partnerships with financial service providers and significant investments have enabled Western Union to develop a robust digital platform. This platform&#39;s strength has made it a preferred partner for efficient global money transfers and advancing digitization in underserved regions.
<h2>Western Union&#39;s Stock Price Performance</h2>
Shares of Western Union have dipped 0.7% year to date against the industry&#39;s 8.8% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/af/80259.jpg?v=1602165044" />
Image Source: Zacks Investment Research
<h2>WU&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
WU currently carries a Zacks Rank #2 (Buy).&nbsp;
Some other top-ranked stocks in the Business Services space are Duolingo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duol#NASDAQ">DUOL</a>), RCM Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcmt#NASDAQ">RCMT</a>) and AppLovin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/app#NASDAQ">APP</a>), each currently sporting a Zacks Rank #1 (Strong Buy).
The bottom line of Duolingo outpaced estimates in each of the last four quarters, the average surprise being 92.09%. The Zacks Consensus Estimate for DUOL&#39;s 2024 earnings is pegged at $1.87 per share, which indicates a more than five-fold increase from the year-ago figure. The consensus mark for revenues implies growth of 38.6% from the year-ago number. The consensus mark for DUOL&#39;s 2024 earnings has moved 7.5% north in the past 60 days.&nbsp;
RCM Technologies&#39; earnings outpaced estimates in three of the trailing four quarters and matched the mark once, the average surprise being 17.49%. The Zacks Consensus Estimate for RCMT&#39;s 2024 earnings indicates an improvement of 10.4% from the year-ago figure. The same for revenues also implies growth of 5.3% from the prior-year reading. The consensus mark for RCMT&#39;s 2024 earnings has moved 2.2% north in the past 60 days.&nbsp;
The bottom line of AppLovin outpaced estimates in each of the last four quarters, the average surprise being 21.06%. The Zacks Consensus Estimate for APP&#39;s 2024 earnings is pegged at $3.46 per share, which indicates a nearly four-fold increase from the year-ago figure. The consensus mark for revenues implies growth of 35.2% from the year-ago actual. The consensus mark for APP&#39;s 2024 earnings has moved 13.1% north in the past 60 days.
Shares of Duolingo and AppLovin have gained 24% and 238.2%, respectively, year to date. However, RCM Technologies stock has lost 31% in the same time frame.
<a href="https://www.zacks.com/stock/news/2345644/western-union-expands-footprint-in-chile-with-khipu-partnership?cid=CS-BENZ-FT-analyst_blog|company_news_finance_sector-2345644">To read this article on Zacks.com click here.</a>

Latin America

Offerings

DUOL

RCMT

Western Union Expands Footprint in Chile With Khipu Partnership

OSTX

OS Therapies shares are trading higher after the company announced the completion of its Phase 2b clinical trial for OST+HER2 in recurred osteosarcoma and is preparing to request an FDA Type C meeting to adjust protocol. It's data analysis and topline results are expected in Q4 2024.

Cryptocurrency markets are trading lower as geopolitical tensions continue to loom over global financial markets.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$60,619.33&nbsp;</td>
<td>&nbsp;-1%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,342.84&nbsp;</td>
<td>&nbsp;-3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$134.89</td>
<td>&nbsp;-5.8%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.103</td>
<td>&nbsp;-0.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.0000159</td>
<td>&nbsp;-3%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 13.4% and daily active addresses falling by 15.9%. Transactions greater than $100,000 are down from 9,410 to 8,750 &nbsp;in a single day. Exchanges netflows are down by 4,310.1%.</li>
<li>Coinglass data reports 93,852 traders were liquidated in the past 24 hours for $263.49 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41171878/franklin-templeton-seeks-sec-approval-for-dual-bitcoin-ethereum-index-etf">Franklin Templeton Seeks SEC Approval For Dual Bitcoin, Ethereum Index ETF</a></li>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41171711/visa-teams-up-with-bbva-to-issue-fiat-backed-tokens-on-blockchain-networks-plans-initial-pilot-b">Visa Teams Up with BBVA To Issue Fiat-Backed Tokens On Blockchain Networks, Plans Initial Pilot By 2025</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41170643/grayscale-launches-new-fund-for-aave-expands-investment-product-line">Grayscale Launches New Fund For AAVE, Expands Investment Product Line</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41159486/swift-targets-2025-to-test-digital-currency-trades-as-central-authorities-look-to-keep-pac">SWIFT Targets 2025 To Test Digital Currency Trades As Central Authorities Look To Keep Pace With Bitcoin&#8217;s Efficiency</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Ethena (CRYPTO: ENA )</td>
<td>&nbsp;$0.2871</td>
<td>&nbsp;-13.8%</td>
</tr>
<tr>
<td>Beam (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/beam/usd">BEAM</a>)</td>
<td>&nbsp;$0.01479</td>
<td>&nbsp;-12.6%</td>
</tr>
<tr>
<td>Fantom (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ftm/usd">FTM</a>)</td>
<td>&nbsp;$0.6051</td>
<td>&nbsp;-9.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices around the $60,000 mark, crypto chart analyst Ali Martinez marked $60,365 as the key Bitcoin level to watch. A break below this would take Bitcoin to $57,420. If this level holds, the crypto king will <a href="https://x.com/ali_charts/status/1841882152528486606">rebound</a> to $63,300, according to the analyst.
CryptoCon tweeted that the Bitcoin bull market starts in two months, according to their analysis.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The real <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> bull market begins in 2 months. November 28th, 2024. <a href="https://t.co/d3XHRviZTQ">pic.twitter.com/d3XHRviZTQ</a>
&mdash; CryptoCon (@CryptoCon_) <a href="https://twitter.com/CryptoCon_/status/1841871403567514106?ref_src=twsrc%5Etfw">October 3, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Santiment <a href="https://x.com/santimentfeed/status/1841889999463002294">data</a> pointed out that with Bitcoin dropping 9.2% since its $66,400 local high on Sep. 27, public sentiment towards crypto has cooled considerably. The analytics firm thinks this mood change is &#8220;encouraging, considering markets typically always move the opposite direction of the crowd&#8217;s expectation.&#8221;
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41166146/would-bitcoin-drop-if-a-war-in-the-middle-east-breaks-out-yes-but-theres-a-catch">Would Bitcoin Drop If A War In The Middle East Breaks Out? Yes, But There&#8217;s A Catch</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BEAM

$BTC

$DOGE

$ETH

$FTM

$SHIB

$SOL

Bitcoin, Ethereum, Dogecoin Drop Again, Continue Defying 'Uptober' Sentiments: Watch This Key Level For A Rebound To $63K, Says Analyst

Airline stocks have endured a <a href="https://www.benzinga.com/news/24/10/41124443/whats-going-on-with-delta-united-and-spirit-airlines-shares-tuesday">year of turbulence</a>, reflected by wild swings in share price, industry expectations and earnings. Recent insider trades of airline companies could indicate where the industry will head next.
The Trades: <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga Edge compiles information </a>on insider trade filings.
Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) experienced a <a href="https://www.benzinga.com/markets/equities/24/10/41156975/southwest-airlines-director-rakesh-gangwal-invests-over-100m-in-shares-amid-elliott-managements-">flurry of insider activity</a> in recent days. Director Rakesh Gangwal invested over $100,000,000 in Southwest shares in late September and early October. Executive Chairman Gary C Kelly <a href="https://www.benzinga.com/quote/LUV/insider-trades">bought $1,000,000 of Southwest</a> shares in late September.
Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) is the largest American airline company. The Atlanta-based giant experienced several insider sales in early 2024. President Glen W Hauenstein sold $4,904,600 in Delta stock in April, over 30% of his total holding. Executive Vice President Peter W Carter sold $2,500,000 of Delta shares that month, over 25% of his position.
Delta has experienced a volatile year. Its share price rose over 30% from January to mid-May, but a subsequent drawdown erased much of its gains. A recovery followed from August to late September.
Several Allegiant Travel Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) executives <a href="https://www.benzinga.com/quote/ALGT/insider-trades">have sold shares</a> in 2024. Chief Marketing Officer Scott DeAngelo sold over $1,000,000 in Allegiant stock in May. DeAngelo has since <a href="https://ir.allegiantair.com/news/news-details/2024/Allegiant-Announces-Resignation-of-Executive-Vice-President-and-Chief-Marketing-Officer-Scott-DeAngelo/default.aspx">resigned</a> from the company. Chief Operating Officer Frank Wilper and Director Gary Ellmer also made sales in the spring and summer.
Why it Matters: Insider trading activity is often viewed as a valuable indicator of a company's future prospects. When top executives or board members buy or sell shares, it can signal their confidence—or lack thereof—in the company's performance. In the case of airline stocks, this insider movement may be especially relevant as the industry navigates a turbulent environment marked by fluctuating demand, rising fuel costs, and post-pandemic recovery.
For investors, tracking these insider trades provides a critical lens into how industry leaders perceive future risks and opportunities, which can guide their own strategies in an increasingly volatile market.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/sports/24/09/41053573/hurricane-helene-disrupts-flights-sports-events-disney-operations-affected-regions-stocks-to-watch">Hurricane Helene Disrupts Flights, Sports Events, Disney Operations: Affected Regions, Stocks To Watch</a></li>
</ul>
Photo: Tupungato/Shutterstock.com

Travel

Insider Trades

ALGT

Will Airlines Soar Or Stall? What Insider Trades Say About Industry's Future

TCBP

TC BioPharm shares are trading higher after the company announced an AI partnership with Carnegie Mellon University for donor screening.

Macquarie analyst Tim Nollen maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Outperform and raises the price target from $72 to $90.

ROKU

Macquarie Maintains Outperform on Roku, Raises Price Target to $90

Proficient Auto Logistics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) shares are trading higher on Thursday. Stifel analyst J. Bruce Chan reiterated a Buy rating on the stock <a href="https://www.benzinga.com/quote/PAL/analyst-ratings">with a price target of $21.00.</a>
The analyst writes that a prolonged port strike could pressure volumes at the company. While a backlog of under a week should be manageable this quarter, longer disruptions could extend impacts into 2025.
The auto-hauling sector offers greater yield benefits than the broader dry van truckload market, as ad hoc moves can command 2-3 times the average contract pricing, adds the analyst.
Chan says that while lower volume does create some negative operating leverage, its impact is less severe due to fewer lost backhauls and a smaller terminal network compared to LTL.
The analyst writes that Proficient&#8217;s stock has faced pressure recently due to an unexpected management departure, a weak third-quarter FY24 operating environment, and ongoing port strikes.
However, Chan notes the equity has overcorrected for these short-term disruptions, which should have minimal impact on 2025 valuations.
The analyst maintains 2024 and 2025 EPS estimates at $0.88 and $1.54, respectively.
Price Action: PAL shares are up 4.55% at $13.80 at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41171072" target="_blank" rel="noreferrer noopener">Amazon Accused of Union-Busting After Drivers Unionize, NLRB Files Complaint</a></li>
</ul>

Proficient Auto Logistics Sees Stock Bounce Amid Short-Term Disruptions, Analyst Stays Bullish

In the last three months, 6 analysts have published ratings on DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for DT Midstream, presenting an average target of $79.33, a high estimate of $87.00, and a low estimate of $72.00. This upward trend is evident, with the current average reflecting a 11.73% increase from the previous average price target of $71.00.
<img src="https://www.benzinga.com/files/images/story/2024/1727982092_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of DT Midstream among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$66.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DT Midstream. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DT Midstream compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of DT Midstream's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of DT Midstream's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DTM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DT Midstream analyst ratings.</a>
<h2>About DT Midstream</h2>
DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates revenue from pipeline, storage, and gathering systems, substantially all of which are located in the Midwestern U.S., Eastern Canada, Northeastern U.S., and Gulf Coast regions.
<h3>DT Midstream's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: DT Midstream displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.93%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: DT Midstream's net margin excels beyond industry benchmarks, reaching 39.34%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): DT Midstream's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.3%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): DT Midstream's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.07%, the company may face hurdles in achieving optimal financial performance.
Debt Management: DT Midstream's debt-to-equity ratio is below the industry average at 0.76, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 6 Analyst Recommendations For DT Midstream

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has reported a promising first half of 2024, focusing on a financially de-risked...

RedHill Biopharma Streamlines for Growth in H1 2024

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has reported a significant reduction in mortality rates among moderate to s...

RedHill Reports Opaganib Reduces COVID-19 Deaths

RedHill Biopharma regains compliance with Nasdaq

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced compliance with Nasdaq's minimum bid price requirement, ensur...

RedHill Biopharma Achieves Nasdaq Compliance

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has notified shareholders of amendments to its Proxy Statement related to t...

RedHill Biopharma Announces ADS Ratio Change

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced that its drug Talicia&#xAE; is now recommended as a first-line tre...

RedHill's Talicia Advances as Preferred H. pylori Treatment

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced the postponement of its Annual General Meeting of Shareholder...

RedHill Biopharma Postpones Shareholder Meeting

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. recently held its Annual General Meeting, with shareholders approving all p...

RedHill Biopharma Shareholders Approve Key Resolutions

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced a new U.S. patent for Opaganib, targeting the treatment of CO...

RedHill Biopharma Secures Opaganib COVID-19 Patent

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has renewed its contract with Medi-Cal, ensuring Talicia's continued availabilit...

Comments

Redhill Biopharma

Interés en corto

Redhill Biopharma (NASDAQ:RDHL) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL